GSK Investigational Site

Lancaster, Pennsylvania 19096

0 studies enrolling now · 14 studies all time

What they study most

Acute Coronary Syndrome, Anaemia, Cirrhosis, Liver, HIV Infections, Incontinence, Urinary and Urinary Bladder, Overactive, Infection, Human Immunodeficiency Virus, Infections, Papillomavirus, Irritable Bowel Syndrome (IBS), Irritable Colon, Lung Cancer, Non-Small Cell, Neoplasms, Prostate, Non-alcoholic Fatty Liver Disease

Studies at this site

• Phase 2b Study of GSK4532990 in Adults With NASH — Running, not enrolling
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) — Completed
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• Dolutegravir Expanded Access Study — Completed
• A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor — Stopped early
• Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age — Completed
• Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects — Completed
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• ARI103094-Follow-Up Study for REDUCE Study Subjects — Completed
• Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy — Completed
• A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder — Completed
• Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men — Completed
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy — Completed